This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2020
ASCO GU 2020
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2020 Bladder Cancer
Viewing 1-20 of 46 articles
ASCO GU 2020: Results from BLASST-1 - Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy.
ASCO GU 2020: Combining Chemotherapy with Novel Agents, Opportunities, and Challenges.
ASCO GU 2020: (NEO-BLADE) Phase II Randomized Placebo-Controlled Neoadjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer
ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma
ASCO GU 2020: The Efficacy of Two Cycles of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Patients.
ASCO GU 2020: Sequencing Chemotherapy and Surgery in Upper Tract Urothelial Cancers
ASCO GU 2020: Replacing TURBT with mpMRI for Staging MIBC: Pilot Data from the BladderPath study
ASCO GU 2020: Germline DNA Copy Number Polymorphism to Predict the Efficacy of BCG Therapy for Non-Muscle Invasive Bladder Cancer
ASCO GU 2020: Randomized Phase III trial for Treatment of Muscle-Invasive Urothelial Bladder Cancer: Preliminary Results of the GETUG/AFU V05 VESPER Trial on Toxicity and Pathological Responses
ASCO GU 2020: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma - Preliminary Durability Results from Study EV-103
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle-Invasive Urothelial Carcinoma: Subtyping of High-risk Muscle Invasive Urothelial Carcinoma
ASCO GU 2020: Opportunities and Limitations of Genomics in Everyday Practice: Circulating Tumor DNA (ctDNA)
ASCO GU 2020: Practicing Beyond Clinical Trial Data: Real-World Challenges in Urothelial Carcinoma
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle-Invasive Urothelial Carcinoma: Adjuvant Options in High-Risk Disease After Primary Intervention
ASCO GU 2020: Circulating Tumor Cells: Opportunities in Muscle Invasive Bladder Cancer
ASCO GU 2020: Adjuvant Options in High-Risk Muscle Invasive Bladder Cancer After Primary Intervention
ASCO GU 2020: Medical Oncology Perspective - Best of Journals: Urothelial Carcinoma
ASCO GU 2020: Risk Stratification and Management of High-Risk Muscle Invasive Urothelial Carcinoma: Circulating Tumor DNA
ASCO GU 2020: Adjuvant Options in High-Risk Disease After Primary Intervention
ASCO GU 2020: Upper Tract Disease: Topical Therapy, Systemic Therapy
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free